ReviewWorld journal of gastroenterology2011
miRNAs in precancerous lesions of the gastrointestinal tract.
Review in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Atrophic gastritis and gastric cancer tissue miRNome analysis reveals hsa-miR-129-1 and hsa-miR-196a as potential early diagnostic biomarkers.World journal of gastroenterology · 2022Article
- Deep learning for diagnosis of precancerous lesions in upper gastrointestinal endoscopy: A review.World journal of gastroenterology · 2021Review
- Molecular Alterations in Gastric Intestinal Metaplasia.International journal of molecular sciences · 2021Review
- miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma.International journal of molecular sciences · 2021Review
- Values of miR-34a and miR-218 expression in the diagnosis of cervical cancer and the prediction of prognosis.Oncology letters · 2018Article
- Article
- Gastric cancer: The times they are a-changin'.World journal of gastrointestinal oncology · 2015Review
- Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.Oncotarget · 2014Article
- Article
- Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.Molecules (Basel, Switzerland) · 2014Review
- The p53/microRNA connection in gastrointestinal cancer.Clinical and experimental gastroenterology · 2014Review
- High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2014Article
- MicroRNA-21 as a potential colon and rectal cancer biomarker.World journal of gastroenterology · 2013Review
- MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia.Clinical and translational gastroenterology · 2013Article
- Up-regulation of Ago2 expression in gastric carcinoma.Medical oncology (Northwood, London, England) · 2013Article
- Surveillance for gastrointestinal malignancies.World journal of gastroenterology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In spite of the well-established understanding of the phenotypic lesions occurring in the shift from native epithelia to invasive (adeno) carcinoma, the molecular typing of the precancerous changes in the gastrointestinal tract remains unreliable. In recent years, no biomarkers have aroused as much interest as the miRNAs, a class of non-coding RNA molecules that function as endogenous silencers of numerous target genes. Aberrant miRNA expression is a hallmark of human disease, including cancer. Unlike most mRNAs, miRNAs are both long-living in vivo and very stable in vitro. Such characteristics allow their testing in paraffin-embedded tissue samples, which is essential in the biological profiling of small (phenotypically characterized) preneoplastic lesions of the gastrointestinal tract (as well as in other fields of human pathology). The upcoming challenge lies in the reliable identification of disease-specific targets of dysregulated miRNAs, to enable miRNA testing in the clinical management of the secondary prevention of gastrointestinal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.